SGEN
Seagen Inc. (acquired by Pfizer; no SGEN listing)
Is SGEN Halal?
Pfizer completed Seagen's acquisition in December 2023 and SGEN was delisted; cancer-medicine analysis is retained without substituting Pfizer ratios.
What You Should Know
SGEN is a preserved Seagen route. Pfizer's merger became effective on December 14, 2023, after which Seagen ceased to be a public company. Targeted cancer therapies remain generally permissible in the qualitative analysis, while drug ingredients and clinical-material questions remain relevant; no current standalone SGEN quantitative screen is applicable.
⚠️ Concerns
- •SGEN was acquired and delisted in December 2023
- •Animal-derived research materials
- •Drug ingredients and clinical manufacturing
- •SGEN is a preserved Pfizer-acquisition alias; the URL is unchanged
Current quantitative Sharia screen
Based on issuer-status figures for the period ended 2023-12-14; calculated 2026-07-15.
- Financial
- Not calculated
- Overall
- Not calculated
Not calculated because Seagen was acquired and delisted in December 2023.
- Financial
- Not calculated
- Overall
- Not calculated
No current standalone Seagen financial statement is available.
- Financial
- Not calculated
- Overall
- Not calculated
Not calculated for the delisted SGEN security.
- Financial
- Not calculated
- Overall
- Not calculated
SGEN has no current public-market price or market-cap series.
Business-activity disclosure
Seagen historically developed targeted cancer therapies. Life-saving medicines are generally permissible in principle, while drug ingredients, manufacturing and clinical materials remain qualitative; SGEN is no longer publicly traded.
Limitation: No current standalone Seagen balance sheet, revenue statement or public share price exists after Pfizer's acquisition.
Purification
No current standalone SGEN issuer income is available for purification.
Inputs, assumptions and primary sources
- Pfizer's merger with Seagen became effective on December 14, 2023; SGEN ceased to be a public company and was delisted.
- No Pfizer segment figures are substituted for a standalone SGEN screen, so numerical ratios are intentionally not calculated.
- The route and existing cancer-medicine qualitative analysis are preserved.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →